Antonio Fojo is an Oncology physician affiliated with Columbia University Irving Medical Center. OpenAlex indexes 245 publications with 18,071 citations (h-index 55); ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
161 Fort Washington Ave
New York, NY 100323729
Telephone
212-342-5155Provider last certified this registry record 26 Apr 2023.
Clinical trials
- LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
Sponsor: Antonio Fojo
- Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Sponsor: Columbia University
- Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Sponsor: Antonio Fojo
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20251 payment
- Daiichi Sankyo Inc.Program year20243 payments
- E.R. Squibb & Sons, L.L.C.Program year20233 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2020–2024 per NIH RePORTER. The latest:
1 awards on record per NIH RePORTER; the itemized rows are on their way. Why? →
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics
Seminars in Oncology
2023 - Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward
The Lancet Global Health
2022 - Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics
Clinical Cancer Research
2020 - Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models
Clinical Cancer Research
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Martin Leon, MD
Columbia University Irving Medical Center
Stanley Fahn, MD
Columbia University Irving Medical Center
Rebecca Hahn, MD
Columbia University Irving Medical Center
Susheel Kodali, MD
Columbia University Irving Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”